74 related articles for article (PubMed ID: 7720109)
41. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
42. [The relation between p53 expression and lymph node metastasis of breast cancer].
Chen YH; Cai JJ; Lu YD
Zhonghua Zhong Liu Za Zhi; 1994 Jul; 16(4):266-8. PubMed ID: 7805554
[TBL] [Abstract][Full Text] [Related]
43. Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers.
Sugai T; Habano W; Jiao YF; Suzuki M; Takagane A; Nakamura S
Oncology; 2005; 68(4-6):548-57. PubMed ID: 16037688
[TBL] [Abstract][Full Text] [Related]
44. Interest of investigating p53 status in breast cancer by four different methods.
Thirion A; Rouanet P; Thezenas S; Detournay D; Grenier J; Lopez-Crapez E
Oncol Rep; 2002; 9(6):1167-72. PubMed ID: 12375013
[TBL] [Abstract][Full Text] [Related]
45. p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer.
Brotherick I; Shenton BK; Cowan WK; Angus B; Horne CH; Higgs MJ; Lennard TW
Cancer Immunol Immunother; 1995 Sep; 41(3):146-50. PubMed ID: 7553682
[TBL] [Abstract][Full Text] [Related]
46. [Analysis of DNA ploidy pattern and overexpression of p53 protein in cases of early gastric carcinoma with lymph node metastasis].
Kido K; Sasaki O; Nagahama S; Yamashita Y; Baba M; Tashiro K; Kume T; Shirakusa T
Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():320-3. PubMed ID: 9263523
[TBL] [Abstract][Full Text] [Related]
47. High levels of p53 expression correlate with DNA aneuploidy in (pre)malignancies of the vulva.
van der Avoort IA; van de Nieuwenhof HP; Otte-Höller I; Nirmala E; Bulten J; Massuger LF; van der Laak JA; Slootweg PJ; de Hullu JA; van Kempen LC
Hum Pathol; 2010 Oct; 41(10):1475-85. PubMed ID: 20656324
[TBL] [Abstract][Full Text] [Related]
48. [Expression and significance of hTERT mRNA in breast carcinoma and its relation to p53].
Tang F; Gu DH; Wang H; Zhu TF; Zhu HG; Xu ZD; Hu XQ
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):192-5. PubMed ID: 16875603
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time.
Bukholm IR; Husdal A; Nesland JM; Langerød A; Bukholm G
Breast Cancer Res Treat; 2003 Jul; 80(2):199-206. PubMed ID: 12908823
[TBL] [Abstract][Full Text] [Related]
50. Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Li BX; Li J; Luo CL; Zhang MC; Li H; Li LL; Xu HF; Shen YW; Xue AM; Zhao ZQ
Indian J Exp Biol; 2013 Mar; 51(3):208-17. PubMed ID: 23678541
[TBL] [Abstract][Full Text] [Related]
51. Correlative study on the expression of p53 and DNA ploidy in acute nonlymphocytic leukemia.
Lin FR; Yao EG; Zuo LF; Xu SR; Ren JH; Liu SY; Wei JP
J Tongji Med Univ; 1995; 15(3):143-6. PubMed ID: 8731941
[TBL] [Abstract][Full Text] [Related]
52. DNA distributions in human normal, precancerous and cancerous breast tissue. II. Differences in heparin mediated changes in DNA distributions.
Weiss H; Kunde D; Streller B
Oncology; 1988; 45(3):214-23. PubMed ID: 3368198
[TBL] [Abstract][Full Text] [Related]
53. p53 immunostaining in benign breast disease.
Heyderman E; Dagg B
Lancet; 1991 Dec; 338(8781):1532. PubMed ID: 1720855
[No Abstract] [Full Text] [Related]
54. Ultrasound-guided intertumoral injection of contrast agents combined with human p53 gene for the treatment of breast cancer.
Guo JC; Yang YJ; Guo M; Jiang XL
Kaohsiung J Med Sci; 2018 Aug; 34(8):438-446. PubMed ID: 30041761
[TBL] [Abstract][Full Text] [Related]
55. P53 Expression in benign Breast Disease Development: A Systematic Review.
Costa RSS; Silva IFD
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2485-2491. PubMed ID: 32986343
[TBL] [Abstract][Full Text] [Related]
56. Relationship between benign breast disease and cancer.
LEWISON EF; LYONS JG
AMA Arch Surg; 1953 Jan; 66(1):94-114. PubMed ID: 12996204
[No Abstract] [Full Text] [Related]
57. Pigments in breast fluid. What are they?
McDonagh AF
BMJ; 1995 Feb; 310(6976):402-3. PubMed ID: 7866239
[No Abstract] [Full Text] [Related]
58. [Cancer of the breast following removal of benign tumor].
KARGL O
Med Klin; 1951 Feb; 46(6):169-71. PubMed ID: 14826427
[No Abstract] [Full Text] [Related]
59. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken SW; Grizzle WE; Crowe DR; Conner MG; Weiss HL; Sellers MT; Krontiras H; Urist MM; Bland KI
Ann Surg; 2001 May; 233(5):630-8. PubMed ID: 11323501
[TBL] [Abstract][Full Text] [Related]
60. [Quantitative study of P53 gene protein expression in the benign disease and cancer of breast].
Qi FY; Zuo LF; Zhen YJ
Zhonghua Bing Li Xue Za Zhi; 1994 Dec; 23(6):330-3. PubMed ID: 7720109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
